Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 17/20 | 0.45 |
| ▸ | PLK3 | Q9H4B4 | 9/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.39 |
| ▸ | NEK2 | P51955 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2987886 | 1.00 | PLK1 (0.45) | PLK1PLK3CYP3A4CYP2C9IKBKE | |
| SCHEMBL2986965 | 0.90 | PLK1 (0.45) | PLK1PLK3CYP3A4CYP2C9NEK2 | |
| SCHEMBL2986967 | 0.90 | PLK1 (0.45) | PLK1PLK3CYP3A4CYP2C9NEK2 | |
| SCHEMBL2986978 | 0.84 | ALDH1A1 (0.43) | PLK1PLK3CYP3A4CYP2C9IKBKE | |
| SCHEMBL25267168 | 0.83 | PLK1 (0.49) | PLK1PLK3CYP3A4CYP2C9NEK2 | |
| SCHEMBL30426721 | 0.83 | PLK1 (0.49) | PLK1PLK3CYP3A4CYP2C9NEK2 | |
| SCHEMBL2977455 | 0.83 | PLK1 (0.49) | PLK1PLK3CYP3A4CYP2C9NEK2 | |
| Hydrochloric Acid SCHEMBL3118930 | 0.82 | PLK1 (0.49) | PLK1PLK3CYP3A4CYP2C9NEK2 | |
| SCHEMBL4778390 | 0.80 | PLK1 (0.38) | PLK1PLK3CYP3A4CYP2C9NEK2 | |
| SCHEMBL3148252 | 0.80 | PLK1 (0.38) | PLK1PLK3CYP3A4CYP2C9NEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12403198-B2 | Benzimidazole thiophene derivative compounds inducing selective degradation of PLK1 | UPPTHERA (KR) | 2025-09-02 | — | — | US | disclosed |
| US-20230159515-A1 | BENZIMIDAZOLE THIOPHENE DERIVATIVE COMPOUNDS INDUCING SELECTIVE DEGRADATION OF PLK1 | UPPTHERA (KR) | 2023-05-25 | — | — | US | disclosed |
| EP-1922316-B1 | BENZIMIDAZOLE THIOPHENE COMPOUNDS AS PLK MODULATORS | GLAXOSMITHKLINE LLC (US) | 2010-03-03 | — | — | EP | disclosed |
| EP-1937671-B1 | BENZIMIDAZOLE THIOPHENE COMPOUNDS AS PLK INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2009-12-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159515-A1 | BENZIMIDAZOLE THIOPHENE DERIVATIVE COMPOUNDS INDUCING SELECTIVE DEGRADATION OF PLK1 | PLK1, BUB1, BUB1B | PLK1 1/4885PLK3 18/4885CYP3A4 2686/4885 |
| US-12403198-B2 | Benzimidazole thiophene derivative compounds inducing selective degradation of PLK1 | PLK1, BUB1, BUB1B | PLK1 1/4885PLK3 18/4885CYP3A4 2686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.